Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Transplantation for non-resectable colorectal liver metastasis (CRLM) has become accepted for a few, select patients following stringent criteria. With improved understanding of the selective indications, enhanced curation of the donor pool, and by further insight into cancer biology, novel avenues for research may be developed and eventually benefit more patients with non-resectable CRLM.
Work is ongoing to recover UK clinical research capacity and capabililty post COVID-19 pandemic (https://sites.google.com/nihr.ac.uk/thefutureofukclinicalresearch/home), but many of the barriers investigators faced pre-pandemic persist. Taking a more patient-centred approach to reform may help apply lessons learned during the pandemic and facilitate ‘building back better’.
